LinkedIn Message Leads To Advocate-Pharma Pursuit Of Expanded Access

A conversation with Raza Bokhari, MD, executive chairman and CEO, Medicus Pharma, and Meredith Weiss, executive director, Gorlin Syndrome Association When the little red notification adorns your LinkedIn inbox, there’s no telling what kind of message awaits you. Many of us are familiar with dubious connection requests, overly flattering pitches to become part of some “who’s who” list, or college recruiters telling us we’re the perfect candidate for an MBA. But for Raza Bokhari, MD, of Medicus Pharma, one simple message from a diligent and well-researched patient advocate launched a partnership that could lead to previously unattainable treatment for ultra-rare disease patients. In this Q&A, Raza and Gorlin Syndrome Association Executive Director Meredith Weiss describe how the two have begun a fledgling partnership to match Medicus’ SKINJECT noninvasive treatment for basal cell carcinoma with GSA’s patient community, hopefully by way of the FDA’s expanded access, or compassionate use, designation and Commissioner’s National Priority Voucher program. Who approached whom and with what goal in mind? Raza: We have an ongoing clinical study for our novel noninvasive treatment alternative for non-melanoma skin diseases, particularly basal cell carcinoma of the skin. And we have a Phase 2 study that commenced recruiting patients in
Read More